BIO-11006 Inhalation Solution: Phase IIa data

The double-blind, U.S. Phase IIa BREATH 1 trial in 172 patients with moderately severe COPD showed that twice-daily 75 mg BIO-11006 missed the primary endpoint of significantly improving FEV1 from bas...